D. Boral Capital Reaffirms Buy Rating for Can-Fite BioPharma (NYSE:CANF)

D. Boral Capital reaffirmed their buy rating on shares of Can-Fite BioPharma (NYSE:CANF) in a research note published on Tuesday,Benzinga reports. They currently have a $10.00 price target on the stock.

Separately, StockNews.com started coverage on Can-Fite BioPharma in a research note on Tuesday, April 8th. They issued a “sell” rating for the company.

Can-Fite BioPharma Trading Down 3.1 %

Shares of CANF stock opened at $1.26 on Tuesday. The company’s fifty day simple moving average is $1.56 and its 200-day simple moving average is $1.78. Can-Fite BioPharma has a 52 week low of $1.22 and a 52 week high of $4.69. The company has a market cap of $4.46 million, a PE ratio of -0.70 and a beta of 1.37.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. BNP Paribas Financial Markets purchased a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned about 0.71% of Can-Fite BioPharma as of its most recent filing with the Securities and Exchange Commission (SEC). 21.00% of the stock is owned by hedge funds and other institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.